Ras (KRAS or NRAS) Gene Mutation clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • NST-628 Oral Tablets in Subjects With Solid Tumors

    open to eligible people ages 18 years and up

    This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.

    Westwood, Los Angeles 5408522, California 5332921 and other locations

Our lead scientists for Ras (KRAS or NRAS) Gene Mutation research studies include .

Last updated: